Objective: Epidemiological studies imply an association between circulating IGF1 and breast cancer, whereas the role of IGF2, which also acts on the IGF1 receptor, is less settled. This study investigates the association between IGF2 and breast cancer in patients with localized disease. Design: The participants were women with well-characterized, early stage, localized breast cancer (nZ43) and matched healthy women (nZ38), from whom fasting serum levels of IGF-related peptides were measured. Results: In patients, mean free IGF2 was increased (C57%, P!0.001), in spite of reduced total IGF2 levels (K12%, PZ0.003) when compared with controls. Similar changes were seen in free IGF1 (C28%, PZ0.004) and total IGF1 (K16% PZNS). Pro-IGF2 and IGF-binding protein 1 (IGFBP1) were unchanged. IGFBP2 was reduced by 22% in the patients (PZ0.004). The patients showed reduced IGFBP3 protease activity and accordingly increased levels of intact IGFBP3, whereas total IGFBP3 was unchanged. Conclusion: Women with localized, early-stage breast cancer show elevated circulating free IGF1 and IGF2, reduced total IGF2 and alterations in IGFBPs. The changes observed despite minimal cancer disease suggest a role for the circulating IGF system in the progression of breast cancer in women.
Introduction
The insulin-like growth factor (IGF) system is involved with normal cell growth, proliferation, differentiation and survival in an endocrine (i.e. hormonal) and paracrine/autocrine manner (1) . The system comprises IGF1 and IGF2, mostly bound to specific high-affinity IGF-binding proteins (IGFBPs) in the circulation. On target cells the IGFs bind to membrane-bound receptors of which the IGF1 receptor (IGF1R) is widely distributed throughout the body and thought to be the primary mediator of IGFrelated metabolic and growth promoting actions (2) . Insulin receptor type A (IR-A) and hybrids of IR and IGF1R are also activated by IGFs and seem to mediate growth promoting effects as well as metabolic effects depending on the ligand (3). The IGF 2 receptor (IGF2R) has high affinity for IGF2 and may scavenge excess growth factor, reducing pericellular IGF2 levels (4) .
In vitro studies show mitogenic and anti-apoptotic effects of IGF1 mediated through the IGF1R (1) . In vivo evidence includes several large prospective studies and in general they suggest a modestly increased breast cancer risk in individuals with serum total IGF1 levels within the upper normal range (5, 6) . Some studies have investigated the molar ratio of IGF1 to IGFBP3 (a putative marker of free IGF1) in breast cancer (7), whereas only a few studies include direct analysis of free IGF1 (6, (8) (9) (10) .
Analyses of breast tumour tissues have revealed an elevated expression of IGF2 (11) . In the transition zone between normal epithelium and tumour tissue, stromal cells and leucocytes express IGF2 that may stimulate angiogenesis (12) and therefore, IGF2 levels in the pericellular environment may be of importance for carcinogenesis. The addition of IGF2 to cancer cells stimulates proliferation (13) , whereas transfection of the IGF2R into cancer cells inhibits growth and increases apoptosis (14) . In parallel, decreased expression or disrupted ligand binding of the IGF2R has been associated with increased growth potential (15, 16) . In vivo, loss of heterozygosity in the IGF2R gene correlates with poor histological differentiation (17) . However, the amount of clinical studies investigating circulating IGF2 levels in cancer populations is limited.
IGFBPs are expressed by breast tumours depending on oestrogen receptor status, and IGFBP proteases may influence IGF activity in the tumour environment (18) . IGFBP3 has undergone the most thorough investigation, showing IGF1 independent anti-proliferative and pro-apoptotic effects in vitro (19) . However, circulating levels of IGFBP3 have been investigated in several prospective cohort studies with somewhat unequivocal conclusions (5, 6) .
The aim of the present study was to compare the circulating IGF system in women with early stage breast cancer and healthy subjects. To eliminate the effects of disseminated disease on the circulating IGF system, we restricted the study cohort to include well-characterized cancer patients with only small tumours and no metastases or axillary involvement. All participants were studied under fasting conditions to minimize confounding by differences in metabolic state.
Materials and methods

Patient characteristics
A subset of patients and controls were selected from a larger cross-sectional cohort collected at the Department of Oncology R, Odense University Hospital, Denmark. The cohort consisted of patients referred over a period of 4 years. Inclusion criteria were Danish citizenship and a postal address within a certain geographical area. A previous cancer diagnosis was an exclusion criterion. For each cancer patient, one healthy woman from the same geographical region was included, matched by date of birth with the aid of the Danish Central Office of Civil Registration. Fasting blood samples were drawn either prior to surgery (patients) or on an examination day (controls) and stored at K80 8C until analysis. The cohort has been described with clinical examination and anthropometric measures including body composition by bioimpedance measurement (Tetrapolar analyzer, 500 mA, 50 kHz, Animeter, Denmark) according to (20) and questionnaires. Questionnaires were developed specifically for this study and included smoking habits, nutrition, menopausal status, medication and previous medical conditions including previous cancer disease (Table 1) . Patient characteristics at surgery were described by tumour size, type and grade (21) , oestrogen receptor status (22) and lymph node involvement. From the cohort, we selected cases with minimal disease determined by small tumour size with a histological grading of 2 or less and no lymphatic spread ( Table 2) . Hormone replacement therapy was taken by 2 of cases and 5 of controls. One patient had diabetes and hypertension, but did not otherwise differ from the group. The controls chosen were not matched directly with the selected cases, but chosen randomly from the same inclusion subperiod. This has introduced a skewness in the study subcohort: women above the age of 50 were offered a screening (mammography) at that time, while women aged 50 or less were not. The result is a larger proportion of small tumours among postmenopausal women than among premenopausal women in the cohort. Selecting cases with small tumours only and at the same time selecting controls randomly introduced a small but significant age difference between cases and controls in the study subcohort (Table 1 ). Each participant gave informed consent prior to inclusion and the study was approved by the regional ethical committee on human research.
Immunoassays
Measurements were performed in duplicate within the same assay. The only exception was free IGF1 and IGF2, which were assayed in triplicate. Serum total IGF1 and IGF2 were determined after acid ethanol extraction using non-competitive time-resolved monoclonal immunofluorometric assays (TR-IFMAs) as previously described (23) . Free IGF1 and IGF2 were separated from bound IGFs by ultrafiltration (24); the detection limit in serum was 0.028 mg/l for free IGF1 and 0.055 mg/l for free IGF2. Pro-IGF2 was determined by acid gel chromatography and subsequent TR-IFMA as previously described (25) . Serum IGFBP1 was determined by ELISA (Medix Biochemica, Kauniainen, Finland). Serum IGFBP2 and IGFBP6 were measured by RIA and serum IGFBP3 by IRMA (Diagnostic System Laboratories Inc., Webster, TX, USA). The average with-in assay and in-between assay coefficient of variations (CVs) for the in-house assays were as follows. Total IGF1 and IGF2: !5 and 
Statistical analysis
All variables were natural-log-transformed and tested using the Shapiro-Wilk ù test for normality. For normaldistributed variables, groups were compared using the two-tailed Student's unpaired t-test, otherwise by Wilcoxon rank-sum test. Linear regression analysis was performed to adjust for age, menopausal status and smoking habits. Correlation analysis was performed to assess relationships between variables. A P value of 0.05 or less was considered statistically significant. P values above 0.10 are reported as non-significant (NS). Numbers are reported as mean and 95% confidence intervals of the mean or alternatively as the relative difference of the mean between groups. Data were analysed using Intercooled Stata 8.2 for Windows.
Results
Women with localized breast cancer showed changes in most components of the IGF system when compared with healthy controls (Table 3) . Free IGF2 was increased in spite of reduced total IGF2 levels, values averaging 157% (P!0.001) and 88% (PZ0.003) of control levels respectively. Similar changes were seen in free and total IGF1 with levels averaging 128% (PZ0.004) and 84% (PZNS) of controls respectively (Fig. 1) . Pro-IGF2 was similar in patients and controls comprising w20% of total IGF2 levels ( Table 3) . IGFBP1 levels were unchanged in cancer patients, whereas IGFBP2 levels were reduced to 78% (PZ0.004; Table 3 ). The difference in immunoreactive IGFBP3 levels was NS in the adjusted analysis, whereas levels measured by WLB (intact IGFBP3) were elevated to 109% in cancer patients relative to controls (P!0.001). Accordingly, IGFBP3 proteolysis was reduced (PZ0.01; Table 3 ). IGFBP3 WLB and IGFBP3 proteolysis were inversely correlated (RZK0.42, P!0.001). No differences were observed for IGFBP4 WLB, IGFBP6 or IGF1:IGFBP3 ratio. Neither IGF levels nor IGFBP levels correlated with tumour characteristics (i.e. histology, tumour size).
Discussion
In this cross-sectional study, we observed several abnormalities in the serum concentrations of total and free IGFs as well as IGFBPs in women with localized, early-stage breast cancer. Most notably, free IGF2 was increased in spite of reduced total IGF2 levels in breast cancer patients, and the same pattern was evident for IGF1. Units are ìg/l except for western ligand blots (Arbitrary units/mm 2 ), protease activity (percent) and pro-/total IGF2 (percent). Asterisk (*) indicates a nonparametric statistical test. Crude P: P value of t-test or non-parametric test (the latter indicated by asterisk). Adj.P: P value of linear regression analysis with adjustment for age, menopausal status and smoking habit.
Only a few studies have investigated circulating IGF2 levels in breast cancer patients. We have identified three published cross-sectional studies investigating IGF2 in breast cancer patients (8, 29, 30) . None of these studies found differences in total IGF2 between cancer patients and controls. One potential explanation of why we were able to demonstrate a significant difference in our study may be due to a large degree of homogeneity among our cancer patients. In addition, the early-stage and localized nature of breast disease among cases in our study might be an explanation as well. The negative findings of case-control studies are contrasted with previous findings from our group. In a prospective study, the risk of developing oestrogen-receptor-positive breast cancer increased with rising levels of total IGF2 at baseline, prior to the development of any tumour (31) . There are several similarities in the present study: both populations were Danish and consist of both pre-and postmenopausal women. Furthermore, most cancers were oestrogen receptor positive. On the basis of these two studies IGF2 appears to be involved with the development and progression of breast cancer since both studies show an elevated level of IGF2. The shift from elevated total IGF2 (before the formation of a tumour) towards low total IGF2 and elevated free IGF2 (with the presence of a small tumour) is not clear, but is 
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Total IGF1 levels were reduced in cancer patients, but this was NS after adjusting for age. A prospective study (6) and a meta-analysis (5) found elevated total IGF1 to be a risk factor among premenopausal women, whereas circulating IGF1 was not a risk factor in postmenopausal women. The variation in total IGF1 levels between subjects depends upon age and IGFBP levels. As a consequence diverging results may be obtained from study to study. It has required large studies and metaanalyses to conclude on the possible link between IGF1 levels and development of cancer. Hence, we have limited power to demonstrate differences in total IGF1 most likely due to the limited study size.
We found elevated free IGF1 levels in patients. A large prospective study (6) and other studies (8, 10) did not find any association between breast cancer and free IGF1. The mentioned studies have all used a commercially available assay, which is believed to determine free plus readily dissociable IGF1. However, we know from previous comparisons that there are genuine differences between the two methods, and that they do not necessarily show superimposable results (32) . The ratio of total IGF1 to IGFBP3 has been suggested as a surrogate marker of free IGF1. In our study, there were marked differences regarding free IGF1, but no differences in IGF1:IGFBP3 ratio (Table 3) . Thus, the present data confirm that IGF1:IGFBP3 ratio is not a good marker of free IGF1 (32) .
There is a contrast between in vitro findings of a strong link between the IGF system and cancer and the somewhat conflicting in vivo data. The use of total IGF measurements may be troublesome because of the complex in vivo interaction between the IGFs and their IGFBPs. Total IGF levels are influenced by the binding capacity in serum, which may impede total IGF measurements in reflecting IGF activity, whereas free IGFs determined by ultrafiltration is a measure of unbound IGF available for interaction with IGF and insulin receptors (24) . Our data document the pitfall of using total IGF measurements alone. We found unchanged total IGF1 levels and a decrease in total IGF2, which could be interpreted as a reduced activity of the IGF system, if there was no other contributing data. The increased free IGF1 and IGF2 levels contrast with the above-mentioned interpretation based on total IGFs, and overall our findings indicate that the bioactivity of the IGF system is increased rather than decreased in non-disseminated breast cancer patients (i.e. no metastases). In concert with this view, the elevated levels of free IGF1 and IGF2 may by increased feedback inhibition of the pituitary GH secretion explain the reduced total IGF levels that we speculate are secondary to a diminished synthesis of the major IGF carrier, the GH dependent IGFBP3.
We did not include patients with cancer catabolism, large tumour burdens or disseminated disease, and all participants were sampled under fasting conditions. This eliminated the risk of introducing differences in the IGF system caused by systemic effects of the neoplasias, for instance liver metastases and cancer-related cachexia, which both may affect the circulating IGF system. If carcinomatous tissue has a direct effect on the IGF system, we would expect an association between tumour size and/or volume and changes in IGF-related peptides. This was not observed, possibly due to the small tumour size and range of sizes in the present study. One study found a correlation between circulating free IGF2 and breast tumour size, but surprisingly cancer patients showed lower levels of free IGF2 than matched controls, and noteworthy, these findings only became evident after correcting for the changes in body fluid composition in the post-operative state (10) .
The prospective studies as well as the present study, with marked changes in the circulating IGF levels despite the localized and early nature of the breast cancers included, support the first scenario. Since tumours were small, the differences observed in breast cancer patients may have existed before the development of a tumour. We investigated possible associations between tumour characteristics (histology, tumour size) and levels of IGFs and IGFBPs but found no significant correlations, which opposes the second scenario. However, the present study remains cross sectional, which is a major limitation towards elucidating possible causal relations.
Changes in the IGF-binding capacity caused by IGFBP proteolysis by tumour tissue may result in discrete changes in total IGF levels and marked increases in free IGF levels. For instance following major surgery, an elevated enzymatic degradation of IGFBP3 may explain that levels of total IGF1 are markedly reduced whereas levels of free IGF1 are relatively increased (28) . In the present study, the levels of immunoreactive IGFBP3 were unchanged among cancer patients after adjustment. We also evaluated the amount of intact IGFBP3 by WLB and proteolysis assay. This revealed an increased amount of intact IGFBP3 and reduced proteolysis among breast cancer patients. Thus, the change in IGFBP3 binding capacity is not likely to explain the observed changes in free and total IGF level. Other case-control studies have found reduced immunoreactive IGFBP3 levels (7, 29) . The large prospective studies have yielded unequivocal results. Both increased (5, 31) and unaltered (6) risk were reported for patients with the highest levels of IGFBP3. In a cohort of both pre-and postmenopausal women proteolytic activity has been found unaltered in earlystage breast cancer, increasing with disease in later stages (8) . Our data contribute to the conflicting data regarding IGFBP3 and breast cancer.
Cancer patients showed lower levels of serum IGFBP2 than controls. This binding protein is an important determinant of free IGF2 levels; low IGFBP2 levels may increase the free fraction of IGF2 (33), a hypothesis supported by our data. The IGFBP2 gene is overexpressed in a number of tumours, but its role is unclear (34) . We and others have investigated IGFBP2 expression in different breast cancer cell lines and found that the expression may be a marker of antioestrogen resistance but not cell survival (35) .
Several mechanisms may link the development of breast cancer to the observed changes in IGF1 and IGF2: First, of all, elevated levels of free IGFs may increase IGF1R and induce IR activation, leading to cell proliferation and reduced apoptosis. Secondly, the presence of carcinomatous tissue may alter the IGF system in ways that increase free IGFs (e.g. tumour IGF production or IGFBP proteolysis). Hopefully, future studies will clarify the changes in the IGF system at the tissue level. In conclusion, the elevated levels of circulating free IGF2 found in women with breast cancer may reflect an increased bioactivity of this axis. It is well established that tumour cells produce IGF2 that act locally, enhancing growth promoting and antiapoptotic signalling. The clear changes that were observed despite minimal cancer disease suggest a role for the IGF system in the progression of breast cancer in women.
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